Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALKS |
---|---|---|
09:32 ET | 9839 | 24.175 |
09:34 ET | 900 | 24.07 |
09:36 ET | 800 | 24 |
09:38 ET | 1400 | 24.03 |
09:39 ET | 800 | 23.99 |
09:41 ET | 1606 | 24.11 |
09:43 ET | 2600 | 24.11 |
09:45 ET | 4154 | 24.12 |
09:48 ET | 600 | 24.11 |
09:50 ET | 2580 | 24.23 |
09:52 ET | 1704 | 24.22 |
09:54 ET | 2946 | 24.27 |
09:56 ET | 2525 | 24.29 |
09:57 ET | 1908 | 24.25 |
09:59 ET | 1526 | 24.26 |
10:01 ET | 1899 | 24.18 |
10:03 ET | 400 | 24.18 |
10:06 ET | 2000 | 24.11 |
10:08 ET | 3053 | 24.14 |
10:10 ET | 1450 | 24.13 |
10:12 ET | 556 | 24.12 |
10:14 ET | 24631 | 24.22 |
10:15 ET | 1626 | 24.16 |
10:17 ET | 900 | 24.155 |
10:19 ET | 5185 | 24.19 |
10:21 ET | 600 | 24.18 |
10:24 ET | 1876 | 24.21 |
10:26 ET | 2828 | 24.21 |
10:28 ET | 3740 | 24.145 |
10:30 ET | 600 | 24.14 |
10:32 ET | 4770 | 24.13 |
10:33 ET | 934 | 24.11 |
10:35 ET | 3834 | 24.15 |
10:37 ET | 300 | 24.15 |
10:39 ET | 2300 | 24.13 |
10:42 ET | 3027 | 24.14 |
10:44 ET | 1100 | 24.12 |
10:46 ET | 7240 | 24.12 |
10:48 ET | 2600 | 24.12 |
10:50 ET | 700 | 24.105 |
10:51 ET | 4246 | 24.12 |
10:53 ET | 4533 | 24.11 |
10:55 ET | 1700 | 24.09 |
10:57 ET | 3394 | 24.115 |
11:00 ET | 500 | 24.115 |
11:02 ET | 6695 | 24.1 |
11:04 ET | 1100 | 24.06 |
11:06 ET | 2249 | 24.055 |
11:08 ET | 2540 | 24.07 |
11:09 ET | 200 | 24.075 |
11:11 ET | 400 | 24.07 |
11:13 ET | 5000 | 24.07 |
11:15 ET | 4301 | 24.11 |
11:18 ET | 1796 | 24.11 |
11:20 ET | 1823 | 24.1 |
11:22 ET | 900 | 24.115 |
11:24 ET | 4118 | 24.08 |
11:26 ET | 1000 | 24.085 |
11:27 ET | 2845 | 24.12 |
11:29 ET | 1199 | 24.12 |
11:31 ET | 3282 | 24.105 |
11:33 ET | 2000 | 24.095 |
11:36 ET | 800 | 24.085 |
11:38 ET | 700 | 24.08 |
11:40 ET | 3183 | 24.08 |
11:42 ET | 400 | 24.085 |
11:44 ET | 509 | 24.08 |
11:45 ET | 5180 | 24.08 |
11:47 ET | 6749 | 24.091 |
11:49 ET | 4660 | 24.045 |
11:51 ET | 100 | 24.055 |
11:54 ET | 954 | 24.05 |
11:56 ET | 100 | 24.05 |
11:58 ET | 4783 | 24.04 |
12:00 ET | 9010 | 24.1 |
12:02 ET | 3040 | 24.105 |
12:03 ET | 11838 | 24.05 |
12:05 ET | 2016 | 24.05 |
12:07 ET | 2418 | 24.03 |
12:09 ET | 700 | 24.03 |
12:12 ET | 3587 | 24.05 |
12:14 ET | 2465 | 23.9985 |
12:16 ET | 679 | 23.99 |
12:18 ET | 3390 | 23.97 |
12:20 ET | 4887 | 23.98 |
12:21 ET | 100 | 23.98 |
12:23 ET | 1900 | 23.98 |
12:27 ET | 4159 | 23.97 |
12:30 ET | 5538 | 23.97 |
12:32 ET | 400 | 23.97 |
12:34 ET | 500 | 23.98 |
12:36 ET | 3282 | 23.98 |
12:38 ET | 1600 | 23.985 |
12:39 ET | 2469 | 23.985 |
12:41 ET | 3509 | 24.04 |
12:43 ET | 5009 | 24.03 |
12:45 ET | 1200 | 24.02 |
12:48 ET | 7419 | 23.99 |
12:52 ET | 2818 | 23.96 |
12:54 ET | 4565 | 23.995 |
12:56 ET | 3259 | 23.97 |
12:57 ET | 500 | 23.975 |
12:59 ET | 600 | 23.98 |
01:01 ET | 4323 | 23.98 |
01:03 ET | 1205 | 23.98 |
01:06 ET | 300 | 23.98 |
01:08 ET | 2244 | 24 |
01:10 ET | 4559 | 24.01 |
01:12 ET | 200 | 24.01 |
01:14 ET | 619 | 24.0018 |
01:15 ET | 1609 | 24.01 |
01:17 ET | 1160 | 24.015 |
01:19 ET | 6884 | 24 |
01:21 ET | 3395 | 24 |
01:26 ET | 400 | 24.01 |
01:30 ET | 1500 | 24.02 |
01:32 ET | 100 | 24.02 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alkermes Plc | 4.0B | 6.9x | --- |
Exelixis Inc | 6.3B | 34.3x | -21.77% |
PTC Therapeutics Inc | 2.8B | -4.8x | --- |
Novavax Inc | 2.1B | -6.3x | --- |
P3 Health Partners Inc | 158.7M | -1.0x | --- |
Halozyme Therapeutics Inc | 5.6B | 21.5x | --- |
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.0B |
---|---|
Revenue (TTM) | $1.7B |
Shares Outstanding | 169.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.45 |
EPS | $3.50 |
Book Value | $7.20 |
P/E Ratio | 6.9x |
Price/Sales (TTM) | 2.3 |
Price/Cash Flow (TTM) | 6.0x |
Operating Margin | 29.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.